Human checkpoint kinase 1 (CHK1) is an essential kinase required to preserve genome stability, and is activated by DNA replication blockage through the ataxia-telangiectasia-mutated-and-Rad3-related (ATR)/ATRIP-signaling pathway. In this report, we show that a novel CHK1-interacting protein, FEM1B (human homologue of the Caenorhabditis elegans sex determination fem1 protein), identified by a yeast two-hybrid screen, is involved in the activation of CHK1 by replication stress. Depletion of FEM1B by small interfering RNA in cancer cells impairs the activation of CHK1 kinase activity and attenuates the induction of CHK1 Ser345 phosphorylation upon replication interference. It is to be noted that, CHK2 Thr68 phosphorylation is not altered by FEM1B downregulation. By fractionation, we further demonstrated that FEM1B is able to associate with chromatin, and such association facilitates chromatin loading of the Rad9 protein. Consistently, ATR activity is poorly maintained in FEM1B knockdown cells; and FEM1B-ablated cells are as sensitive to replication block as CHK1-depleted cells. Our study has uncovered an adaptor protein FEM1B, which acts as a bridge linking CHK1 and Rad9, thus facilitating checkpoint signaling induced by replication stress.
Introduction
To ensure faithful passage of the genome, cells initiate the stress-response pathway, namely the cell cycle checkpoint, on encountering environmental or intrinsic genotoxic insults. There are many checkpoints installed, for example, the G1-S checkpoint prevents unscheduled DNA replication, the S-phase checkpoint stops progression of replication forks, and the G2-M checkpoint protects cells from untimely mitotic entry and subsequent catastrophic division (Niida and Nakanishi, 2006; Bartek and Lukas, 2007) . Among these, S-phase checkpoints include three distinct and somehow redundant checkpoints: the replication-dependent intra-S-phase checkpoint (replication checkpoint) that is activated by stalled replication forks to prevent lateorigin firing; the DNA double-strand break-induced and replication-independent intra-S-phase checkpoint (intra-S-phase checkpoint) that is caused by doublestrand DNA breaks outside the active replicons; and the S-M checkpoint that prevents cell division before the genome is fully duplicated (Bartek et al., 2004; Machida and Dutta, 2005) .
In eukaryotic cells, the replication checkpoint is governed by ataxia-telangiectasia-mutated-and-Rad3-related (ATR)-dependent signaling including Rad17, Rad9-Hus1-Rad1 (9-1-1) complex and the mediator protein Claspin. This checkpoint can be induced by UV, hydroxyurea (HU) (ribonucleotide reductase inhibitor) and camptothecin (CPT, topoisomerase-I inhibitor) (Bartek et al., 2004; Cimprich and Cortez, 2008) . The initiating signal is commonly generated by stalled DNA-polymerases associated with replicons, either as a result of UV damage or inhibition of topoisomerase. Such uncoupling of helicases and polymerases generates single-strand DNA, which attracts replication protein A (RPA). Binding of the RPA then recruits and activates the ATR/ATRIP complex (Zou and Elledge, 2003) , resulting in the phosphorylation and activation of downstream mediators and effectors. On the other hand, the 9-1-1 complex is independently loaded onto stalled sites by the Rad17-replication factor C (RFC) complex (Zou et al., 2002) . The reason why two independent-sensor complexes are needed is not entirely clear. However, evidence has emerged indicating that interaction between ATR and Rad9 through TopBP1 is required to sustain ATR activation (Delacroix et al., 2007; Lee et al., 2007) . Moreover, ATR-dependent phosphorylation of Rad17 and Claspin facilitates activation of CHK1 (Kumagai and Dunphy, 2003; Wang et al., 2006) , a crucial downstream effector kinase of ATR. Activation of CHK1 can delay Sphase DNA replication, stabilize stalled replication forks, prevent cell death and block mitotic entry (Chen and Poon, 2008) .
In this study, we explored the CHK1 signaling pathway by a yeast two-hybrid screen to identify potential CHK1-interacting partners. Human FEM1B, a homolog of the nematode fem-1 sex determination gene, was thus isolated. The protein product, FEM1B, contains six ankyrin repeats in the N-terminus and a von Hippel-Lindau (VHL)-box in the C-terminus (Chan et al., 1999; Ventura-Holman and Maher, 2000; Kamura et al., 2004) . Human FEM1B was first identified as a Fas-and tumor necrosis factor receptor (TNFR)-interacting protein that mediates apoptosis when overexpressed in MCF7 cells (Chan et al., 1999; VenturaHolman and Maher, 2000) . It has also been shown to interact with Cul2/Rbx1, and serve as a substrate recognition subunit in an E3 complex with a target yet to be identified (Kamura et al., 2004) .
We present herein evidence that by interacting with CHK1 and likely Rad9, FEM1B functions as an adaptor/mediator in replication stress-induced signaling that leads to the activation of CHK1.
Results

Human FEM1B interacts with CHK1 in vitro and in vivo
To better our understanding of the CHK1 signaling pathway, we earlier conducted a yeast two-hybrid screen to isolate novel CHK1-interacting proteins using the C-terminal domain (amino acids 277-476) of CHK1 as bait. By screening a human testis cDNA library, B3 was isolated, which encodes the C-terminal half (amino acids 245-627) of FEM1B, the human homolog of the mouse Fem1b.
We first confirmed that FEM1B interacts directly with CHK1 by an in vitro glutathione S-transferase (GST) pull-down assay. To determine the interacting domains in FEM1B, various histidine (His)-tagged FEM1B truncation mutants were generated (Figure 1a) . In Figure 1b , GST-CHK1, but not GST, brought down Glutathione S-transferase (GST) pull-down assay was performed with GST or GST-CHK1 proteins and purified His-FEM1B. The amounts of input and pulled down proteins are shown by western blotting. (c) Endogenous FEM1B and CHK1 interact in vivo. HCT116 cells were treated with 20 nM camptothecin (CPT) and collected at indicated times. The interaction was detected by immunoprecipitation with anti-FEM1B followed by immunoblotting with CHK1 antibody (left panels) or by immunoprecipitation with anti-CHK1 followed by immunoblotting with FEM1B antibody (right panels).
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T-P Sun and S-Y Shieh the full length (FL, 1-627), DN (245-627), DC (1-506), and DNDC (245-506) of FEM1B in vitro. When we further divided FEM1B into three small fragments, N (1-252), M (245-471), and C (471-627), both N and M fragments interacted with CHK1, whereas the C fragment failed to interact. Therefore, at least two independent regions in FEM1B mediate the interaction with CHK1, one located in the N-terminal domain and the other resides in the central domain. Possible in vivo interaction between endogenous FEM1B and CHK1 was also investigated. As shown in Figure 1c (left panels), FEM1B in HCT116 cells coimmunoprecipitated with CHK1, suggesting that the two proteins may form a complex in cells. As CHK1 is involved in DNA-damage response, the effect of DNA damage on the interaction was also examined. Interestingly, the amount of coprecipitated CHK1 was significantly diminished after the treatment with the topoisomerase-I inhibitor camptothecin (CPT), indicating that interaction between the two proteins is subjected to regulation by DNA damage. Consistent results were observed when reciprocal immunoprecipitation was performed with anti-CHK1 antibody ( Figure 1c , right panels).
FEM1B ablation by small interfering RNA (siRNA) attenuates CHK1 activation by replication stress Possible functional implications of the interaction were explored. We first determined whether FEM1B could modulate the kinase activity of CHK1 by an in vitro kinase assay, using purified recombinant GST-CHK1 in combination with increasing amounts of bacteriaexpressed, purified His-FEM1B. No observable effect was detected on CHK1-mediated phosphorylation of GST-Cdc25C (amino acids 200-256) (Figure 2a ), indicating that the interaction per se did not impact on the activity of CHK1. It was noted that His-FEM1B was also a CHK1 substrate in this setting; the implication remains to be determined.
Whether the FEM1B protein participates in signaling to CHK1 in cells was then investigated. To address this issue, CHK1 was immunoprecipitated from HCT116 cells transfected with FEM1B-targeting or control siRNA, and the kinase activity was assessed in vitro. As shown in Figure 2b and c, CPT, which induces replication stress, activated the CHK1 activity 12 h posttreatment in control siRNA transfected, but not in FEM1B-depleted cells.
As our data suggested that FEM1B was required for CHK1 activation in cells, we postulated that downregulation of FEM1B in cells could interfere with the replication of stress-induced phosphorylation of CHK1 and CHK1 downstream target proteins. Indeed, CPTinduced CHK1 phosphorylation at Ser345 was mitigated in FEM1B-ablated cells (Figure 3a and b) , so was phosphorylation at Ser317 (data not shown). Similarly, accumulation of Cdc2 Tyr15 phosphorylation was also dampened, an indication of failure in the inhibition of Cdc25A by CHK1 (Figure 3a) . In contrast, FEM1B ablation had no effect on CHK2 Thr68 phosphorylation upon CPT treatment (Figure 3b ). The effect of FEM1B depletion was also observed with another FEM1B-targeting siRNA (FEM1B-3), thus excluding an offtarget effect (Figure 3c ). In addition, this observation was made with another cell line, HeLa, using the replication blocker HU (Figure 3d ). Thus, our data indicate that FEM1B has a specific role in mediating CHK1 activation in vivo.
Stress-induced chromatin association of Rad9 is diminished in FEM1B-ablated cells While FEM1B has been reported to interact with the cytoplasmic domains of Fas and the TNF receptor in cells (Chan et al., 1999) , whether it can also reside in the nuclei was unclear. We therefore performed cell fractionation to verify the localization of FEM1B. As revealed in Figure 4a , FEM1B was detected in both the cytoplasm (C) and the nucleus (N), with the majority in the former. This is consistent with the distribution of ectopically expressed green fluorescence protein (GFP)-FEM1B (data not shown). In the nucleus, the FEM1B protein level increased slightly after the CPT treatment (30 nM for 6 h) ( Figure 4a ). Additional fractionation studies revealed the presence of FEM1B in the chromatin fraction (P2); the level of association was not altered by HU treatment (Figure 4b ).
Since FEM1B depletion negatively regulates CHK1 activation and CHK1 activation requires loading of the Rad9-Hus1-Rad1 complex onto chromatin by the clamp loader Rad17-RFC, we investigated whether FEM1B ablation interfered with the chromatin loading of these damage sensors. Consistent with earlier reports, HU treatment did not alter chromatin association of Rad17 and ATR (Zou et al., 2002; Dart et al., 2004) ; the FEM1B downregulation resulted in a slight decrease in chromatin-associated Rad17, but no detectable change in ATR (Figure 4b ). In contrast, a marked decrease in Rad9 in chromatin fraction (P2), but not in soluble nuclear fraction (S2) was observed when FEM1B was ablated by targeting siRNA (Figure 4b ). In addition, slight reduction in chromatin association was observed for Hus1 in FEM1B knockdown cells and for Rad1 after HU treatment in the same cells, suggesting that a significant portion of Rad9 was recruited by FEM1B independent of the 9-1-1 complex ( Figure 4c ). It should be noted that consistent with decreased CHK1 activation, Rad17 Ser645 phosphorylation was also reduced upon downregulation of FEM1B (Figure 4b ).
On the basis of the data presented above, we speculated that, apart from interacting with CHK1, FEM1B may also be in contact with Rad9, therefore recruiting or maintaining chromatin association of Rad9. This possibility was first investigated and confirmed in vitro by a GST pull-down assay. GSTRad9, but not GST, brought down His-FEM1B even in the presence of ethidium bromide, suggesting that the interaction between the two proteins can be direct and did not require the mediation of DNA (Figure 4d ). Further attempts to coimmunoprecipitate cellular Rad9 and FEM1B were not successful, implying that, in vivo, FEM1B as a novel CHK1 mediator T-P Sun and S-Y Shieh either the two proteins interact transiently or additional modification may be involved.
Decreased ATR activity in FEM1B-knockdown cells Upon replication stress, activation of ATR is coupled to the Rad9-Hus1-Rad1 complex through Top-BP1 (Delacroix et al., 2007; Lee et al., 2007) . Because loading of Rad9 onto chromatin was impaired in FEM1B-downregulated cells, we wondered if ATR activity may also be similarly affected, thus contributing to reduced CHK1 Ser345 and Rad17 Ser645 phosphorylation. To investigate this possibility, ectopically expressed Flag-ATR was immunoprecipitated from FEM1B-knockdown 293T cells, and its kinase activity was assayed in vitro using GST-CHK1 291À360 as a substrate. The kinase activity of Flag-ATR increased after the HU treatment in control siRNA transfected cells as evidenced by increased phosphorylation of the substrate including that on Ser317 (Figure 5a ). In contrast, in cells with downregulated FEM1B, Flag-ATR failed to respond to HU, and the activity remained unaltered (Figure 5a , compare the 5-h time points). The effect of FEM1B downregulation on the activation of ATR was also observed in HCT116 cells when endogenous ATR was examined using GST-p53 1À80 as a substrate (Figure 5b ). In this case, induction of Rad17 Ser645 phosphorylation by CPT was also abrogated upon knockdown of FEM1B, further supporting the role of FEM1B in the regulation of ATR activity.
Collectively, our data indicate that FEM1B contributes to CHK1 activation by facilitating the ATR kinase activity toward CHK1 by Rad9 chromatin loading.
FEM1B downregulation by siRNA impairs CHK1-mediated cell protection after replication stress CHK1 has been reported to have a primary role in the protection of cells from apoptosis induced by replication inhibitors such as CPT, HU, and thymidine (Rodriguez and Meuth, 2006) . As FEM1B regulated the activation of CHK1, whether FEM1B plays a role in the antiapoptotic response was examined. HCT116 cells In vitro kinase assays were performed by incubating increasing amounts of purified full-length FEM1B (0.4-2.5 mg) with purified glutathione S-transferase (GST)-CHK1 kinase using GST-Cdc25C 200À256 as substrate. Bovine serum albumin (BSA) was added to adjust the amounts of total protein in each reaction. GST-CHK1 kinase activity was measured by autoradiography. The input recombinant proteins were detected by silver stain or western blotting as shown in the right panel. (b) FEM1B ablation reduces the kinase activity of endogenous CHK1. IPkinase assay, performed using CHK1 immunoprecipitated from control or FEM1B depleted HCT116 cells after DMSO or 20 nM camptothecin (CPT) treatment using GST-Cdc25C 200À256 as substrate. Levels of substrate phosphorylation from two independent experiments were quantified and are shown in (c).
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were transfected with either CHK1 or FEM1B-targeting siRNA ( Figure 6a ). As reported earlier (Han et al., 2002; Rodriguez and Meuth, 2006) , control siRNA transfected cells showed an accumulation of G2-phase cells 48 h after the CPT treatment ( Figure 6b ). In comparison, CHK1-ablated cells showed less G2 phase accumulation and instead, a higher sub-G1 content (Figure 6b and c). FEM1B-knockdown cells exhibited a similar increase in sub-G1 content but no apparent effect on G2 arrest (Figure 6b and c) perhaps because of a normal activation of CHK2 (Figure 3b ). Combined depletion of the CHK1 and the FEM1B did not further increase the sub-G1 population (data not shown), suggesting that CHK1 and FEM1B work in the same pathway to guard against replication stress-induced cell death. Consistently, in clonogenic survival assays, both CHK1-and FEM1B-knockdown cells were more sensitive to the CPT treatment than the control (Figure 6d ). Taken together, these results lend further support to FEM1B facilitating ATR-CHK1 signaling and thus, promoting cell survival under replication stress.
Discussion
In this study, we have identified a novel CHK1-interacting protein, FEM1B, which is involved in the regulation of phosphorylation and the activation of CHK1 by facilitating chromatin loading of the Rad9 protein after replication blockage. We presented evidence that FEM1B is associated with chromatin, and ablation of FEM1B expression leads to impaired Rad9 chromatin loading and attenuated ATR activity. Most importantly, FEM1B, like CHK1, functions in replication stress to protect cells from apoptotic cell death. The human FEM1B protein was first identified by its homology with the mouse Fem1b, which, along with Fem1a and Fem1c, is a homologue of the Caenorhabditis elegans sex determination gene, fem1 (Chan et al., FEM1B as a novel CHK1 mediator T-P Sun and S-Y Shieh 1999; Ventura-Holman and Maher, 2000; Krakow et al., 2001; Ventura-Holman et al., 2003) . The fem1 family of proteins shows relatively high degree of sequence homology; for example, human FEM1B shares 30% amino acid identity with C. elegans fem-1 and is only six amino acid residues different from mouse Fem1b (Ventura-Holman et al., 1998; Chan et al., 1999) , implying a possible conserved function for the fem1 proteins. That the sex determination pathways in mammals and C. elegans are quite different and that fem-1 protein is expressed at the same levels in both sexes (Gaudet et al., 1996) , point to the existence of an unexplored function other than sex determination. Data presented in this study further support such a possibility. By serving as a bridge between two important checkpoint regulators, CHK1 and Rad9, FEM1B may ensure proper checkpoint response. However, unlike the lethality observed on Chk1 deletion, Fem1b knockout embryos were able to survive (Lu et al., 2005) , suggesting that, unlike CHK1, murine Fem1b may not be involved in the regulation of cell cycle progression in unperturbed cells.
Structurally, the N-terminal domain of FEM1B contains a stretch of six ankyrin repeats (AR), a motif known to mediate protein-protein interaction and found in a myriad of proteins including those involved in cell-cycle regulation (Li et al., 2006) . In addition to its Cytosolic (C) and nuclear (N) extracts were prepared from HCT116 cells treated with 30 nM CPT for 6 h and were analyzed by Western blotting. a-Tubulin and poly ADP ribose polymerase (PARP) were used as the loading control for cytosolic and nuclear fractions, respectively. (b) FEM1B downregulation diminishes Rad9 but not ATR chromatin loading. FEM1B-knockdown HCT116 cells were treated with 2 mM HU for 3 h and collected for chromatin extraction. Origin recognition complex subunit 2 (ORC2) was used as the chromatin marker. S1, S2 and P2 represent, respectively, the cytosolic, the soluble nuclear and the chromatin fractions. Lower panel shows levels of Rad17, Rad17 phospho-Ser645, Rad9 and ATR in P2 fraction (chromatin-bound) after normalization to ORC2. (c) FEM1B depletion reduces chromatin association of Hus1 and Rad1 after HU treatment. Experiments were conducted as in (b) except that Hus1-and Rad1-specific antibodies were used for detection. (d) FEM1B interacts directly with Rad9 in vitro, independent of DNA. Glutathione S-transferase (GST) pull-down assays were performed with recombinant His-FEM1B and GST-Rad9 in the presence or absence of ethidium bromide (EtBr, 400 mg/ml). GST-Rad9, but not GST, brought down FEM1B even in the presence of EtBr, which disrupts protein-DNA interaction.
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possible involvement in the direct interaction between FEM1B and CHK1 as suggested in Figure 1b , AR has also been implicated in the interaction of p53-53BP2 (Gorina and Pavletich, 1996) and CDK6/4-p16INK4a (Russo et al., 1998; Jeffrey et al., 2000) . On the other hand, AR in FEM1B may also participate in the association with chromatin either directly or indirectly, a prospect yet to be explored. The prominent cytoplasmic localization of FEM1B would likely raise an issue, as to how the cytoplasmic and nuclear population of FEM1B differentiate from each other. Although our data have implicated nuclear FEM1B in the regulation of early checkpoint signaling, they do not exclude the possibility that cytoplasmic FEM1B may also be involved in checkpoint regulation, especially in light of the significant presence of CHK1 in the cytoplasm (Figure 4a) . The relationship between CHK1 and FEM1B may continue to exist in the cytoplasm, but the relevant circuit and impact await further investigation. On the other hand, it is fully possible that cytoplasmic FEM1B may have other unidentified function.
It is now widely accepted that Claspin is the major mediator in checkpoint signaling leading to CHK1 activation (Kumagai and Dunphy, 2000; Chni and Chen, 2003; Kumagai et al., 2004) . Although the details remain incomplete, emerging evidence indicates that ATR/ATRIP, the Rad17-RFC loader, and the Rad9-Rad1-Hus1 clamp complex are all required for the interaction between Claspin and CHK1. In response to replication stress, Rad17 phosphorylation by ATR is required for Claspin recruitment and CHK1 activation (Wang et al., 2006) ; ATR-dependent phosphorylation of Claspin mediates its interaction with CHK1 (Kumagai and Dunphy, 2003) . Furthermore, depletion of Claspin from the Xenopus egg extract abrogated the activation of CHK1 (Kumagai and Dunphy, 2000) . In spite of these findings, Claspin ablation in HeLa cells did not impede CHK1 activation and only minimally affected the later phase of CHK1 phosphorylation (Chini et al., 2006) , suggesting that an alternative pathway does exist. In addition to our findings with FEM1B, a recent study implicated the involvement of another protein, MCL-1, a Bcl-2 family member, in the activation of CHK1 by DNA damage (Jamil et al., 2008) . Overexpression of MCL-1 causes CHK1 phosphorylation at activating sites, whereas knockdown abolished it (Jamil et al., 2008) . How this is accomplished is unknown except that MCL-1 also interacts with activated CHK1 in damagetreated cells. These studies, together with ours, reveal a complex picture of CHK1 activation in which at least three mediator/adaptor molecules are present upstream of CHK1. Existing evidence suggests these adaptors may have different modes of action. While Claspin acts downstream of Rad9, FEM1B works in parallel with or upstream of Rad9. The interaction between MCL-1 and CHK1 is facilitated by damage; in contrast, FEM1B interaction with CHK1 is diminished upon CHK1 phosphorylation. Different cells may utilize distinct adaptors; for example, Claspin may play a larger role in U2OS cells than in HeLa cells (Chini et al., 2006) . Or the requirement may be sequential, such that FEM1B is needed for recruitment of Rad9 and to bring in CHK1; once CHK1 is phosphorylated, it then dissociates from chromatin-bound FEM1B. In this scenario, Claspin and MCL-1 may participate in the later phase of CHK1 phosphorylation. Apart from all these, there is a possibility that the requirement for different adaptors may be damage type-specific. An obvious example is given by a recent study that shows in Xenopus extract CHK1 activation by DNA double strand break is mediated by both Claspin and BRCA1 (Yoo et al., 2006) . Further investigation will be needed to verify these possibilities. Nevertheless, the results presented in this study have unraveled a new avenue for possible intervention in cancer treatment targeting checkpoint proteins.
Figure 5 FEM1B ablation dampens replication stress-induced ATR kinase activity. (a) Flag-ATR kinase activity is reduced in FEM1B-knockdown cells after HU treatment. 293 T cells were cotransfected with FEM1B siRNA and Flag-tagged ATR and treated with 2 mM HU for indicated times. Flag-ATR was immunoprecipitated from lysates with anti-Flag agarose, and the kinase activity was assayed in vitro using Glutathione S-transferase (GST)-CHK1 291À360 as substrate. The phosphorylation of CHK1Ser317 was also assessed by immunoblotting. Substrate input was Ponceau S-stained. (b) Endogenous ATR kinase activity is diminished in FEM1B ablated cells after camptothecin (CPT) treatment. HCT116 cells transfected with FEM1B or control siRNA were treated with 1 mM CPT for 1 h, and lysates were immunoprecipitated with ATR antibody. IPkinase assays were performed using GST-p53 1À80 as substrate.
Materials and methods
Yeast two-hybrid screen For the yeast two-hybrid screen, the C-terminal domain of CHK1 (residues 277-476) was cut from pBS-CHK1 with AvaI and KpnI, and the blunt fragment was recloned into the SmaI site of pDBTrp (Invitrogen, Carlsbad, CA, USA). This was used as bait to screen a human testis cDNA library cloned in the pACT2 vector (Clontech, Mountain View, CA, USA). The yeast strains and assay conditions were those used in the ProQuest two-hybrid system (GIBCO, Rockville, MD, USA).
Plasmids and recombinant proteins
For the in vitro interaction experiment, the expression vector for His-tagged full-length (FL) FEM1B was made from the pXJ-HA-F1Aa vector (a kind gift from Dr V Yu, Institute of Molecular and Cell Biology, Singapore), and subcloned into the BamHI and KpnI sites of pRSET A vector (Invitrogen). His-FEM1B-N (amino acids 1-252) was made by utilizing the internal HindIII site. For generating His-FEM1B-M (amino acids 245-471), BamHI and BglII sites were used instead. His-FEM1B-C (amino acids 471-637) was made by cutting pGEX-B3 with BglII and XhoI, and the isolated fragment was recloned into the same sites in pRSET C. His-FEM1B-DC (1-506), His-FEM1B-DN (245-627), and His-FEM1B-DNDC (245-506) were made by using the internal BamHI and PstI sites and were cloned into pRSET A.
The human RAD9 cDNA was provided by Dr HB Lieberman (Columbia University) and was subsequently myc-tagged and recloned into the BamHI and XhoI sites of pGEX4T-1 (Amersham Biosciences, Piscataway, NJ, USA) for bacterial expression.
For the construction of GST-CHK1 291À360 , a fragment corresponding to amino acids 291-360 of CHK1 was amplified by PCR and cloned into the EcoRI and BamHI sites of pGEX-4T-1. was kindly provided by Dr C Prives (Department of Biological Sciences, Columbia University). Recombinant His-FEM1B proteins, GST and GST fusion proteins were all expressed in and purified from Escherichia coli essentially as described earlier (Wei et al., 2005) .
Baculovirus-expressed, recombinant GST-CHK1 was purified from insect cells as described earlier (Shieh et al., 2000) .
GST pull-down assay Purified GST or GST-CHK1 proteins were incubated with recombinant His-FEM1B FL or various deletion mutants for 30 min at 30 1C in Co-IP buffer (20 mM Tris, pH 7.5, 150 mM 
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NaCl, 10% glycerol, 0.1% NP-40, 5 mM MgCl 2 , 1 mM EDTA, 1 mM DTT and 10 mM PMSF with protease inhibitor cocktail) containing 2 mg/ml BSA. The mixtures were then incubated with 12 ml glutathione-Sepharose beads (50%) for 1 h at 4 1C with occasional mixing. The beads were then precipitated, washed three times in the same buffer, resuspended in SDS sample buffer, boiled and analyzed by SDS-PAGE followed by immunoblotting as described below. Interaction between His-FEM1B and GST-Rad9 in the presence or absence of ethidium bromide was examined as described (Ou et al., 2007) .
Cell culture, lysis, immunoblotting and coimmunoprecipitation The human colon carcinoma HCT116 and cervical carcinoma HeLa cells were cultured in RPMI (Hyclone, Logan, UT, USA) and DMEM (Hyclone), respectively, supplemented with 10% fetal bovine serum (Invitrogen) and antibiotics. 293T, a transformed human embryonic kidney cell line, was maintained in DMEM plus 10% equine serum (Invitrogen) and antibiotics.
Cell lysis, immunoblotting, and coimmunoprecipitation were performed as described earlier (Wei et al., 2005) .
siRNA transfection and DNA damage treatments Transfection of siRNA was performed as described earlier using Oligofectamine (Invitrogen) and siRNA at a final concentration of 0.15-0.2 mM. The sequences targeted by FEM1B-1, FEM1B-3 and CHK1 siRNA were 5 0 -GCTTCT CAACCGGTCTGAA-3 0 , 5 0 -GCAGACTGGACATTGTGA A-3 0 and 5 0 -GGTGCCTATGGAGAAGTTC-3 0 , respectively. A siRNA with random sequence, 5 0 -AAGTCAATATGCGA CTGATGG-3 0 , was used as a control. All siRNAs were synthesized and annealed by Qiagen (Valencia, CA, USA).
Antibodies
Rabbit polyclonal anti-FEM1B antibody was raised against recombinant His-tagged full-length protein by LTK Biolaboratories (Touyuan, Taiwan). The anti-FEM1B antiserum was further purified by affinity against antigen immobilized on nitrocellulose membrane. As a comparison, the commercial anti-F1Aa (FEM1B) antibody (AB3608) from Chemicon (Temecula, CA, USA) gave the same results in immunoblotting.
Antibodies purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) were: anti-His (sc-8036), anti-GST (sc-138), anti-GFP (sc-8334), anti-myc (sc-40), anti-Rad17 (sc-17761), anti-CHK1 (sc-8408; sc-7898), anti-Cdc2 (sc-54), and anti-phospho-Thr68 CHK2 (sc-16297-R). Anti-actin (A2066) and anti-a-tubulin (T6074) were from Sigma-Aldrich (St Louis, MO, USA). Other antibodies used for immunoblotting were the following: anti-CHK1 (A300-162A, Bethyl Laboratories, Montgomery, TX, USA), anti-phospho-CHK1 (Ser345, C4200-05, US Biological, Swampscott, MA, USA and #2341, Cell Signaling, Danvers, MA, USA; Ser317, A300-163A, Bethyl Laboratories), anti-Claspin (A300-266A, Bethyl Laboratories), anti-phospho-Rad17 (Ser645, R0445-06, US Biological), anti-Rad9 (R90820, BD Transduction laboratories, San Jose, CA, USA), anti-Rad1 (ab5363, Abcam, Cambridge, UK), anti-Hus1 (H00003364-B01, Abnova, Taipei, Taiwan), anti-ATR (PC128, Oncogene, Boston, MA), anti-HA (HA.11, Covance, Emeryville, CA, USA), anti-CHK2 (K0087, MBL, Nagoya, Japan), anti-PARP (Roche, Mannheim, Germany), anti-ORC2 (M055-3, MBL) and antiphospho-Cdc2. (Tyr15, Cell Signaling).
In vitro kinase assay and IP kinase assay The in vitro kinase assay was performed as described earlier by incubating insect cell-purified recombinant GST-CHK1 with bacterially expressed proteins.
For the CHK1 IP/kinase assay, HCT116 cells were lysed in IP buffer containing 50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA and 1 mM DTT, with protease and phosphatase inhibitors. CHK1 was first immunoprecepitated from cell lysates with anti-CHK1 (sc-7898) antibody and protein G beads at 4 1C for 2-3 h, washed once in IP buffer, once in high salt buffer (50 mM Tris, pH 7.5, 1 M NaCl, 1% Triton X-100, 10% glycerol, 1 mM DTT and 1 mM PMSF), once in IP buffer and twice in kinase buffer. Kinase reactions were then performed as described above using GSTCdc25C 200À256 as substrate.
For assaying the kinase activity of endogenous ATR, HCT116 cells were lysed by sonication in ATR lysis buffer (20 mM Hepes, pH 7.4, 1.5 mM MgCl 2 , 1 mM EGTA, 0.2% Tween 20, 10 mM NaF and 1 mM DTT) containing protease and phosphate inhibitors. IP was carried out in the same lysis buffer in the presence of anti-ATR antibody and protein G beads at 4 1C for 3-4 h. The IP lysates were then washed twice with ATR lysis buffer, once with high salt buffer (100 mM Tris pH 7.5, 600 mM NaCl, 1 mM DTT) and twice with kinase buffer (10 mM Hepes pH 7.4, 50 mM NaCl and 10 mM MgCl 2 ). Kinase reaction was performed by the addition of 1-2 mg GSTp53 1À80 , 5 mCi [g-32 P] ATP and cold ATP to a final 5 mM at 30 1C for 20 min. The reaction products were subsequently analyzed as above.
To assess the kinase activity of Flag-ATR ectopically expressed in 293T cells, conditions for IP kinase assay were essentially as described by Zhao and Piwnica-Worms (2001) .
Cell fractionation
Cytosolic (C) and nuclear fractions (N) were prepared as described (Ou et al., 2007) . To isolate chromatin fractions, cells were first resuspended in buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.34 M sucrose, 10% glycerol, 1 mM DTT) containing protease and phosphatase inhibitors. Triton X-100 (0.1%) was then added and the cells were incubated for 2-3 min on ice. Nuclei were collected in pellets by low-speed centrifugation (4 min, 1300 Â g, 4 1C). The supernatant (S1) was further clarified by high-speed centrifugation to remove cell debris and insoluble aggregates. Nuclei were washed once in buffer A and then lysed in buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT and protease inhibitors). After centrifugation (4 min, 1700 Â g, 4 1C), supernatants (S2) were removed, and insoluble chromatin was washed once in buffer B and centrifuged again under the same conditions. The final chromatin pellet (P2) was resuspended in RIPA and protein sample buffer, boiled and resolved by SDS-PAGE followed by immunoblotting.
Flow cytometry analysis
Cell-cycle distribution was measured by propidium iodide staining and FACS analysis using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) as described (Wei et al, 2005) . At least 10 000 gated cells were counted for each sample. The histogram data were curve fit, and the percentage of cells in each phase of the cell cycle was estimated according to the DNA content.
Clonogenic survival assay HCT116 cells were transfected with siRNA for 2 days and replated at a density of 2000 cells per well on 12-well dishes in FEM1B as a novel CHK1 mediator T-P Sun and S-Y Shieh triplicate. The next day, cells were treated with indicated concentrations of CPT for 6 h, washed once with PBS, and incubated in normal medium for 10 days. Colonies were fixed and stained as described earlier (Ou et al., 2007) .
